既往二尖瓣手术后再次二尖瓣置换术的结局:经导管途径的基准
该研究回顾了1992年至2015年520例成人再次二尖瓣置换术(re-MVR)的住院与生存结局,其中273例既往二尖瓣修复(pMVP)、247例既往二尖瓣置换(pMVR)。基准队列中pMVP组与pMVR组手术死亡率均为4.1%,全队列pMVP组5% vs pMVR组9%(P=.087)。结论认为re-MVR是高危手术,但在经过选择的患者中结果可接受,pMVP患者长期生存优于pMVR患者。
要点
- 全队列手术死亡率pMVP组5%(14/273) vs pMVR组9%(23/247),P=.087。
- 基准队列两组手术死亡率均为4.1%(3例),P=1.0。
- 慢性肾病、感染性心内膜炎、pMVR、≤1年早期再手术及年龄与生存降低相关。
核心结论
- 再次二尖瓣置换术是高危手术,但在经过选择的患者如本基准人群中结果可接受。
- 既往二尖瓣修复患者相比既往二尖瓣置换患者长期生存更好。
- 这些结果将作为经导管二尖瓣瓣中瓣/环中瓣置换的基准。
研究设计与样本
- 回顾性分析1992年1月至2015年6月单中心24年间520例成人再次二尖瓣置换术患者,其中273例既往二尖瓣修复(pMVP)、247例既往二尖瓣置换(pMVR)。
- 基准队列定义为可能符合经导管二尖瓣瓣中瓣/环中瓣置换条件的孤立再次二尖瓣置换术,包括73例既往二尖瓣修复带成形环患者和74例既往生物瓣二尖瓣置换患者。
主要发现
- 全队列平均年龄pMVP组64±12岁 vs pMVR组63±15岁(P=.281),基准队列相似。
- 全队列手术死亡率pMVP组5%(14/273) vs pMVR组9%(23/247)(P=.087)。
- 基准队列两组手术死亡率均为4.1%(各3例)(P=1.0)。
- 基准队列中位再手术时间pMVP组9.8年 vs pMVR组9.1年。
- Cox比例风险分析显示慢性肾病(HR 2.47;95%CI 1.77-3.44)、感染性心内膜炎(HR 1.49;95%CI 1.07-2.07)、pMVR(HR 1.45;95%CI 1.12-1.89)、≤1年早期再手术(HR 1.49;95%CI 1.02-2.17)及年龄(HR 1.04/岁;95%CI 1.03-1.05)与再次二尖瓣置换术后生存降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: With the emergence of transcatheter mitral valve-in-valve/ring replacement for deteriorated bioprostheses or failed repair, comparative clinical benchmarks for surgical repeat mitral valve replacement (re-MVR) are needed. We present in-hospital and survival outcomes of a 24-year experience with re-MVR. METHODS: From January 1992 to June 2015, 520 adult patients underwent re-MVR; 273 had undergone prior mitral valve repair (pMVP) and 247 had undergone prior MVR (pMVR). A benchmark cohort of isolated re-MVR was defined based on potential eligibility for transcatheter mitral valve-in-valve/ring replacement, resulting in 73 pMVPs with previous annuloplasty rings and 74 pMVRs with previous bioprosthetic valves for comparison. RESULTS: For the entire cohort, mean age was 64 ± 12 years for pMVP patients and 63 ± 15 years for pMVR patients (P = .281), which was similar for the benchmark cohort. Overall operative mortality was 14 out of 273 (5%) for pMVP versus 23 out of 247 (9%) for pMVR (P = .087). There were 3 operative deaths (4.1%) in both groups of the benchmark cohort (P = 1.0). For the benchmark cohort, median time to reoperation was 9.8 years for pMVP and 9.1 years for pMVR. Cox proportional hazard analysis showed that chronic kidney disease (hazard ratio [HR], 2.47; 95% CI, 1.77-3.44), endocarditis (HR, 1.49; 95% CI, 1.07-2.07), pMVR (HR, 1.45; 95% CI, 1.12-1.89), early reoperation ≤ 1 year (HR, 1.49; 95% CI, 1.02-2.17), and age (HR, 1.04/y; 95% CI, 1.03-1.05) were associated with decreased survival after re-MVR. CONCLUSIONS: A re-MVR is a high-risk operation, but in carefully selected patients such as our benchmark population, it can be performed with acceptable results. Patients undergoing pMVP also have better long-term survival compared with patients undergoing pMVR. These results will serve as a benchmark for transcatheter mitral valve-in-valve/ring replacement.
引用
- Ejiofor JI, Hirji SA, Ramirez-Del Val F, et al. Outcomes of repeat mitral valve replacement in patients with prior mitral surgery: A benchmark for transcatheter approaches. J Thorac Cardiovasc Surg. 2018. PMID: 29759741. doi:10.1016/j.jtcvs.2018.03.126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。